JP4808785B2 - インスリン組成物および組成物の製造方法 - Google Patents

インスリン組成物および組成物の製造方法 Download PDF

Info

Publication number
JP4808785B2
JP4808785B2 JP2008547953A JP2008547953A JP4808785B2 JP 4808785 B2 JP4808785 B2 JP 4808785B2 JP 2008547953 A JP2008547953 A JP 2008547953A JP 2008547953 A JP2008547953 A JP 2008547953A JP 4808785 B2 JP4808785 B2 JP 4808785B2
Authority
JP
Japan
Prior art keywords
insulin
ethoxy
human insulin
acylated
desb30 human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008547953A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009522231A (ja
JP2009522231A5 (enExample
Inventor
スヴェンド ハヴェルンド，
フランチセク フバレク，
ヘレ， ビルク オルセン，
イブ ヨナセン，
トマス ヘーグ−イェンセン，
アンネ プラム，
ウラ リベル−マドセン，
Original Assignee
ノボ・ノルデイスク・エー／エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36888823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4808785(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノボ・ノルデイスク・エー／エス filed Critical ノボ・ノルデイスク・エー／エス
Publication of JP2009522231A publication Critical patent/JP2009522231A/ja
Publication of JP2009522231A5 publication Critical patent/JP2009522231A5/ja
Application granted granted Critical
Publication of JP4808785B2 publication Critical patent/JP4808785B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008547953A 2005-12-28 2006-12-21 インスリン組成物および組成物の製造方法 Active JP4808785B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05113021.9 2005-12-28
EP05113021 2005-12-28
PCT/EP2006/070104 WO2007074133A2 (en) 2005-12-28 2006-12-21 Compositions comprising an acylated insulin and zinc and method of making the said compositions

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2010174030A Division JP5026567B2 (ja) 2005-12-28 2010-08-02 インスリン組成物および組成物の製造方法
JP2011008924A Division JP2011121963A (ja) 2005-12-28 2011-01-19 インスリン組成物および組成物の製造方法

Publications (3)

Publication Number Publication Date
JP2009522231A JP2009522231A (ja) 2009-06-11
JP2009522231A5 JP2009522231A5 (enExample) 2010-09-16
JP4808785B2 true JP4808785B2 (ja) 2011-11-02

Family

ID=36888823

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008547953A Active JP4808785B2 (ja) 2005-12-28 2006-12-21 インスリン組成物および組成物の製造方法
JP2010174030A Active JP5026567B2 (ja) 2005-12-28 2010-08-02 インスリン組成物および組成物の製造方法
JP2011008924A Withdrawn JP2011121963A (ja) 2005-12-28 2011-01-19 インスリン組成物および組成物の製造方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2010174030A Active JP5026567B2 (ja) 2005-12-28 2010-08-02 インスリン組成物および組成物の製造方法
JP2011008924A Withdrawn JP2011121963A (ja) 2005-12-28 2011-01-19 インスリン組成物および組成物の製造方法

Country Status (10)

Country Link
US (2) US20090074882A1 (enExample)
EP (2) EP1969004B1 (enExample)
JP (3) JP4808785B2 (enExample)
CN (1) CN101389650B (enExample)
AT (1) ATE519780T1 (enExample)
DK (1) DK1969004T3 (enExample)
ES (1) ES2371361T3 (enExample)
PL (1) PL1969004T3 (enExample)
PT (1) PT1969004E (enExample)
WO (1) WO2007074133A2 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011121963A (ja) * 2005-12-28 2011-06-23 Novo Nordisk As インスリン組成物および組成物の製造方法
US8828923B2 (en) 2003-08-05 2014-09-09 Novo Nordisk A/S Insulin derivatives
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US10596229B2 (en) 2010-10-27 2020-03-24 Novo Nordisk A/S Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5248113B2 (ja) * 2004-11-12 2013-07-31 ノヴォ ノルディスク アー／エス ペプチドの安定な処方
ES2438145T3 (es) 2005-02-02 2014-01-16 Novo Nordisk A/S Nuevos derivados de insulina
ES2490243T3 (es) 2005-02-02 2014-09-03 Novo Nordisk A/S Derivados de insulina
JP5202338B2 (ja) 2006-02-27 2013-06-05 ノボ・ノルデイスク・エー／エス 新規インシュリン誘導体
EP2024390B1 (en) * 2006-05-09 2015-08-19 Novo Nordisk A/S Insulin derivative
AU2007247109B2 (en) * 2006-05-09 2012-03-15 Novo Nordisk A/S Insulin derivative
US9018161B2 (en) 2006-09-22 2015-04-28 Novo Nordisk A/S Protease resistant insulin analogues
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
JP5715418B2 (ja) 2007-11-08 2015-05-07 ノボ・ノルデイスク・エー／エス インスリン誘導体
ES2430042T3 (es) * 2007-11-16 2013-11-18 Novo Nordisk A/S Composiciones farmacéuticas estables que comprenden liraglutida y degludec
ES2618073T3 (es) 2008-03-14 2017-06-20 Novo Nordisk A/S Análogos de insulina estabilizados frente a proteasas
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
US10842951B2 (en) 2010-01-12 2020-11-24 Aerami Therapeutics, Inc. Liquid insulin formulations and methods relating thereto
US9180261B2 (en) 2010-01-12 2015-11-10 Dance Biopharm Inc. Preservative free insulin formulations and systems and methods for aerosolizing
WO2011141407A1 (en) * 2010-05-10 2011-11-17 Novo Nordisk A/S Process for the preparation of insulin-zinc complexes
EP2632478B1 (en) 2010-10-27 2019-07-24 Novo Nordisk A/S Treating diabetes melitus using insulin injections administered with varying injection intervals
CN103249427A (zh) 2010-12-14 2013-08-14 诺沃—诺迪斯克有限公司 速效胰岛素联合长效胰岛素
MX342922B (es) 2011-02-01 2016-10-19 Novo Nordisk As Purificacion de insulina.
CN102675452B (zh) 2011-03-17 2015-09-16 重庆富进生物医药有限公司 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物
EP2836508B1 (en) 2012-04-11 2016-06-29 Novo Nordisk A/S Insulin formulations
AU2013255880B2 (en) 2012-05-01 2017-07-20 Novo Nordisk A/S Pharmaceutical composition
IN2015DN03795A (enExample) 2012-10-24 2015-10-02 Inserm Inst Nat De La Santé Et De La Rech Médicale
CN104902922B (zh) 2012-11-13 2017-12-12 阿道恰公司 包含经取代阴离子化合物的速效胰岛素制剂
US20160296602A1 (en) * 2013-03-20 2016-10-13 Novo Nordisk A/S Dosing Regimen
JP6499184B2 (ja) 2013-10-07 2019-04-10 ノヴォ ノルディスク アー／エス インスリン類似体の新規な誘導体
CA2932875A1 (en) * 2014-01-09 2015-07-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
DK3006045T3 (en) 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
CA3011902C (en) * 2015-02-25 2023-08-15 Dance Biopharm, Inc. Liquid insulin formulations and methods relating thereto
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
EP3495384A4 (en) * 2016-08-02 2020-02-26 Jiangsu Hengrui Medicine Co., Ltd. ACYLATED DERIVATIVE OF HUMAN INSULIN OR THE LIKE
EP3821905B1 (en) * 2016-12-16 2022-10-12 Novo Nordisk A/S Insulin containing pharmaceutical compositions
TWI740099B (zh) * 2018-02-01 2021-09-21 大陸商江蘇恒瑞醫藥股份有限公司 含人胰島素類似物的醯化衍生物的藥物組合物及其製備方法
AU2019272401A1 (en) 2018-05-24 2021-01-14 Jiangsu Hengrui Medicine Co., Ltd. Method for preparing precursor of recombinant human insulin or analogue thereof
WO2021185304A1 (zh) * 2020-03-18 2021-09-23 东莞市东阳光生物药研发有限公司 制备长脂肪链二酸衍生物的方法及其应用
CN116583531A (zh) * 2020-11-27 2023-08-11 江苏恒瑞医药股份有限公司 一种制备胰岛素或其类似物的酰化衍生物的方法
WO2022268208A1 (zh) * 2021-06-25 2022-12-29 甘李药业股份有限公司 含酰化胰岛素的药物组合物
CN113896784B (zh) * 2021-10-18 2024-04-16 合肥天麦生物科技发展有限公司 一种胰岛素结晶的制备方法及其产品

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001518915A (ja) * 1997-03-20 2001-10-16 ノボ ノルディスク アクティーゼルスカブ インシュリンと吸収増強剤の共沈殿による治療用粉末の調整法
JP2002527487A (ja) * 1998-10-16 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 肺送達のための安定に濃縮されたインスリン製剤
WO2003094956A1 (en) * 2002-05-07 2003-11-20 Novo Nordisk A/S Soluble formulations comprising monomeric insulin and acylated insulin
JP2004523589A (ja) * 2001-03-23 2004-08-05 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 改善された安定性を有するいかなる量の亜鉛も含有しないかまたはほんの少量の亜鉛しか含有しないインスリン製剤
WO2005012347A2 (en) * 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1212679B (de) 1957-08-03 1966-03-17 Novo Terapeutisk Labor As Verfahren zur Herstellung von Insulinloesungen
GB1042194A (en) 1962-04-30 1966-09-14 Olin Mathieson Insulin preparations
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3907676A (en) 1970-07-28 1975-09-23 Novo Terapeutisk Labor As Process for purifying insulin
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
GB1492997A (en) 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
JPS5767548A (en) 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
US4652548A (en) 1981-08-27 1987-03-24 Eli Lilly And Company Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4876322A (en) 1984-08-10 1989-10-24 Siemens Aktiengesselschaft Irradiation cross-linkable thermostable polymer system, for microelectronic applications
DE3562922D1 (en) 1984-08-17 1988-06-30 Bayer Ag Thermoplastic moulding masses with flame-retarding properties
DE3433367A1 (de) 1984-09-12 1986-03-20 Robert Bosch Gmbh, 7000 Stuttgart Einrichtung zur steuerung der energiezufuhr zu einer heissen stelle
DK113585D0 (da) 1985-03-12 1985-03-12 Novo Industri As Nye peptider
US5008241A (en) 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JPS61226115A (ja) 1985-03-30 1986-10-08 Mitsubishi Metal Corp 線条体押し出し機
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4764592A (en) 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
JPH04502465A (ja) 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
EP0506792B1 (en) * 1989-12-21 1995-05-17 Novo Nordisk A/S Insulin preparations containing nicotinic acid or nicotinamide
DK45590D0 (enExample) 1990-02-21 1990-02-21 Novo Nordisk As
DK175491D0 (da) 1991-10-18 1991-10-18 Novo Nordisk As Apparat
DK0618807T3 (da) 1991-12-20 2003-03-03 Novo Nordisk As Stabiliseret farmaceutisk formulering omfattende human væksthormon og histidin
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US6869930B1 (en) * 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US6011007A (en) * 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
BR9407508A (pt) * 1993-09-17 1997-01-07 Novo Nordisk As Derivado de insulina composição farmaceutica e processo para o tratamento de diabete em um paciente com necessidade deste tratamento
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
AU3562195A (en) 1994-10-04 1996-04-26 Novo Nordisk A/S Preparations containing aspb28 human insulin and nicotinamide
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5646242A (en) * 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5830999A (en) * 1995-01-26 1998-11-03 Regents Of The University Of California Stabilization of insulin through ligand binding interations
AU720966B2 (en) 1995-03-17 2000-06-22 Novo Nordisk A/S Insulin derivatives
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
DK2275119T3 (da) 1995-07-27 2013-11-11 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
US6451970B1 (en) * 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5866538A (en) * 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US5905140A (en) * 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
PT938502E (pt) 1996-07-11 2005-02-28 Novo Nordisk As Metodo selectivo por acilacao
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
ATE264871T1 (de) 1996-07-26 2004-05-15 Aventis Pharma Gmbh Insulinderivate mit erhöhter zinkbindung
IL119029A0 (en) * 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
AU6611998A (en) 1997-03-20 1998-10-20 Novo Nordisk A/S Therapeutic powder formulation for pulmonary administration, containing crystalline insulin
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
AR012894A1 (es) 1997-06-13 2000-11-22 Lilly Co Eli Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
SI0884053T1 (en) 1997-06-13 2003-02-28 Eli Lilly And Company Stable insulin formulations
EA200000453A1 (ru) 1997-10-24 2000-10-30 Эли Лилли Энд Компани Композиции нерастворимого инсулина
AU757933B2 (en) 1997-10-24 2003-03-13 Novo Nordisk A/S Aggregates of human insulin derivatives
US6451762B1 (en) * 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
US20020155994A1 (en) * 1997-10-24 2002-10-24 Svend Havelund Aggregates of human insulin derivatives
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
AU1375199A (en) 1997-11-12 1999-05-31 Alza Corporation Method for decreasing self-association of polypeptides
CO4970787A1 (es) * 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
WO1999034821A1 (en) * 1998-01-09 1999-07-15 Novo Nordisk A/S Stabilised insulin compositions
US6211144B1 (en) * 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
ES2180511T3 (es) * 1999-01-26 2003-02-16 Lilly Co Eli Formulaciones monodispersas de analogos de insulina acilados hexamericos.
DE60035260T2 (de) 1999-02-22 2007-10-18 The University Of Connecticut, Farmington Neue albuminfreie faktor viii formulierungen
JP2002543092A (ja) 1999-04-27 2002-12-17 イーライ・リリー・アンド・カンパニー 肺投与用インスリン結晶
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US6652886B2 (en) * 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
JP4624600B2 (ja) * 2001-06-08 2011-02-02 トヨタ自動車株式会社 焼結合金、その製造方法およびバルブシート
PT1412384E (pt) 2001-06-28 2008-03-28 Novo Nordisk As Formulação estável de glp-1 modificado
WO2003013573A1 (en) 2001-08-10 2003-02-20 Epix Medical, Inc. Polypeptide conjugates with extended circulating half-lives
US20030068361A1 (en) 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
BR0215029A (pt) 2001-12-20 2005-12-20 Lilly Co Eli Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus
WO2003075950A1 (en) * 2002-03-13 2003-09-18 Novo Nordisk A/S Minimising body weight gain in insulin treatment
JP2005526126A (ja) 2002-05-07 2005-09-02 ノボ　ノルディスク　アクティーゼルスカブ インスリンアスパルト及びインスリンデテミアを含む可溶性製剤
US20050232899A1 (en) 2002-05-31 2005-10-20 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
KR100615389B1 (ko) 2002-08-23 2006-08-25 (주)헬릭서 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품
NZ562480A (en) 2002-10-29 2009-08-28 Alza Corp Stabilized, solid-state polypeptide particles
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
JPWO2004069259A1 (ja) 2003-02-07 2006-05-25 味の素株式会社 糖尿病治療剤
ES2349128T3 (es) 2003-02-19 2010-12-28 Novartis Ag Antigeno de glucoproteina sima 135 expresado en celulas de tumor humanas metastasicas.
DE602004029630D1 (de) 2003-03-04 2010-12-02 Technology Dev Co Ltd Injizierbare Insulinzubereitung mit Langzeitwirkung und Verfahren zur dessen Herstellung und Verwendung
ES2382157T3 (es) 2003-06-25 2012-06-05 Novo Nordisk Health Care Ag Composición líquida de polipépttidos del factor VII
US20050054818A1 (en) 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
EP1644411A2 (en) 2003-07-11 2006-04-12 Novo Nordisk A/S Stabilised insulin compositions
ES2402592T3 (es) 2003-08-05 2013-05-07 Novo Nordisk A/S Nuevos derivados de insulina
KR101293503B1 (ko) 2003-08-14 2013-08-07 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물
EP1663295A2 (en) 2003-09-01 2006-06-07 Novo Nordisk A/S Stable formulations of peptides
ES2229931B1 (es) 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
JP2007532096A (ja) * 2003-11-14 2007-11-15 ノボ　ノルディスク　アクティーゼルスカブ アシル化されたインスリンの製造方法
BRPI0418115A (pt) 2003-12-23 2007-04-17 Pharmacia Corp formulação lìquida estável de hormÈnio de crescimento
DE602005014962D1 (de) 2004-03-12 2009-07-30 Biodel Inc Insulinzusammensetzungen mit verbesserter wirkstoffabsorption
EP1750750B1 (en) 2004-06-01 2012-02-01 Ares Trading S.A. Method of stabilizing proteins
WO2006008238A1 (en) 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
MX2007001663A (es) 2004-08-12 2007-04-10 Schering Corp Formulacion de interferon pegilado estable.
AU2005277357B2 (en) 2004-08-17 2011-08-04 Regeneron Pharmaceuticals, Inc. IL-1 antagonist formulations
JP5248113B2 (ja) 2004-11-12 2013-07-31 ノヴォ ノルディスク アー／エス ペプチドの安定な処方
ES2391776T3 (es) 2004-11-22 2012-11-29 Novo Nordisk A/S Formulaciones solubles, estables conteniendo insulina con una sal de protamina
CN101106979A (zh) 2005-01-21 2008-01-16 阿尔扎公司 具有改善的稳定性的含有至少一种反离子的用于涂覆微针的治疗性的肽试剂
ES2438145T3 (es) 2005-02-02 2014-01-16 Novo Nordisk A/S Nuevos derivados de insulina
ES2490243T3 (es) 2005-02-02 2014-09-03 Novo Nordisk A/S Derivados de insulina
WO2007041481A1 (en) 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
KR20080064171A (ko) 2005-10-20 2008-07-08 나스텍 파마수티컬 컴퍼니 인코포레이티드 속효성 인슐린의 비강내 투여
JP4808785B2 (ja) 2005-12-28 2011-11-02 ノボ・ノルデイスク・エー／エス インスリン組成物および組成物の製造方法
JP5202338B2 (ja) 2006-02-27 2013-06-05 ノボ・ノルデイスク・エー／エス 新規インシュリン誘導体
CN101454019A (zh) 2006-04-12 2009-06-10 百达尔公司 速效和长效胰岛素联合制剂
WO2007121256A2 (en) 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
AU2007247109B2 (en) * 2006-05-09 2012-03-15 Novo Nordisk A/S Insulin derivative
EP2024390B1 (en) 2006-05-09 2015-08-19 Novo Nordisk A/S Insulin derivative
WO2007135117A2 (en) 2006-05-24 2007-11-29 Novo Nordisk A/S Soluble, stable insulin-containing formulations
US9018161B2 (en) 2006-09-22 2015-04-28 Novo Nordisk A/S Protease resistant insulin analogues
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
US8962794B2 (en) 2007-08-15 2015-02-24 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
JP5715418B2 (ja) 2007-11-08 2015-05-07 ノボ・ノルデイスク・エー／エス インスリン誘導体
ES2430042T3 (es) * 2007-11-16 2013-11-18 Novo Nordisk A/S Composiciones farmacéuticas estables que comprenden liraglutida y degludec
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
EP2352513B1 (en) 2008-10-30 2016-09-14 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
WO2011141407A1 (en) 2010-05-10 2011-11-17 Novo Nordisk A/S Process for the preparation of insulin-zinc complexes
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
EP2389945A1 (en) 2010-05-28 2011-11-30 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising AVE0010 and insulin glargine
EP2632478B1 (en) 2010-10-27 2019-07-24 Novo Nordisk A/S Treating diabetes melitus using insulin injections administered with varying injection intervals
HRP20191793T1 (hr) 2010-10-27 2019-12-27 Novo Nordisk A/S Liječenje dijabetesa melitusa injekcijama inzulina koje se primijenjuje u različitim intervalima injiciranja
MX342922B (es) 2011-02-01 2016-10-19 Novo Nordisk As Purificacion de insulina.
ES2927800T3 (es) 2011-03-01 2022-11-11 Nutrition 21 Llc Composición de insulina y cromo para el tratamiento y la prevención de diabetes, hipoglicemia y trastornos relacionados
WO2013037754A2 (en) 2011-09-13 2013-03-21 Novo Nordisk A/S Adaptive system for optimizing a drug dosage regimen over time
EP2836508B1 (en) 2012-04-11 2016-06-29 Novo Nordisk A/S Insulin formulations
AU2013255880B2 (en) 2012-05-01 2017-07-20 Novo Nordisk A/S Pharmaceutical composition
US20160296602A1 (en) 2013-03-20 2016-10-13 Novo Nordisk A/S Dosing Regimen
US9839579B2 (en) 2013-04-24 2017-12-12 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
AU2018317810A1 (en) 2017-08-17 2020-03-19 Novo Nordisk A/S Novel acylated insulin analogues and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001518915A (ja) * 1997-03-20 2001-10-16 ノボ ノルディスク アクティーゼルスカブ インシュリンと吸収増強剤の共沈殿による治療用粉末の調整法
JP2002527487A (ja) * 1998-10-16 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 肺送達のための安定に濃縮されたインスリン製剤
JP2004523589A (ja) * 2001-03-23 2004-08-05 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 改善された安定性を有するいかなる量の亜鉛も含有しないかまたはほんの少量の亜鉛しか含有しないインスリン製剤
WO2003094956A1 (en) * 2002-05-07 2003-11-20 Novo Nordisk A/S Soluble formulations comprising monomeric insulin and acylated insulin
WO2005012347A2 (en) * 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8828923B2 (en) 2003-08-05 2014-09-09 Novo Nordisk A/S Insulin derivatives
JP2011121963A (ja) * 2005-12-28 2011-06-23 Novo Nordisk As インスリン組成物および組成物の製造方法
US11167035B2 (en) 2005-12-28 2021-11-09 Novo Nordisk A/S Insulin compositions and method of making a composition
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
US10596229B2 (en) 2010-10-27 2020-03-24 Novo Nordisk A/S Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US12226458B2 (en) 2018-06-26 2025-02-18 Novo Nordisk A/S System for providing an up-to-date and long-acting or ultra-long-acting insulin dose guidance recommendation to treat diabetes mellitus
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation

Also Published As

Publication number Publication date
US11167035B2 (en) 2021-11-09
CN101389650B (zh) 2012-10-10
CN101389650A (zh) 2009-03-18
JP2011006428A (ja) 2011-01-13
JP2009522231A (ja) 2009-06-11
EP1969004A2 (en) 2008-09-17
US20140328943A1 (en) 2014-11-06
PL1969004T3 (pl) 2012-01-31
EP1969004B1 (en) 2011-08-10
DK1969004T3 (da) 2011-11-28
PT1969004E (pt) 2011-11-25
JP2011121963A (ja) 2011-06-23
EP2505593A1 (en) 2012-10-03
JP5026567B2 (ja) 2012-09-12
ATE519780T1 (de) 2011-08-15
US20090074882A1 (en) 2009-03-19
WO2007074133A3 (en) 2007-10-11
WO2007074133A2 (en) 2007-07-05
ES2371361T3 (es) 2011-12-30

Similar Documents

Publication Publication Date Title
JP4808785B2 (ja) インスリン組成物および組成物の製造方法
JP2009522231A5 (enExample)
EP2256129B1 (en) Insulin derivatives
JP5721432B2 (ja) アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
EP2262539B1 (en) Insulin albumin conjugates
JP5550338B2 (ja) ペグ化持続型インスリン
JP5730569B2 (ja) アシル及びアルキレングリコール部分を有するインスリンアナログ
CN102037008B (zh) 蛋白酶稳定化的、酰化胰岛素类似物
NO340925B1 (no) Nye insulinderivater
JP2013545782A (ja) 長時間作用型インスリンと組み合わせた速効型インスリン
EP2058330A1 (en) Insulin derivative

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091218

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100802

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20100802

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20100826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110608

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110719

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110817

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140826

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4808785

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140826

Year of fee payment: 3

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250